Pharvaris: Phase 3 Study Design for Recently Initiated RAPIDe-3 Hereditary Angioedema Study

 

• The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, presented at two recent congresses: the 3^rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) and the 2024 HAE International (HAEi) Regional Conference Americas.

https://www.biospace.com/article/releases/pharvaris-announces-phase-3-clinical-study-design-for-recently-initiated-rapide-3-study-and-presents-quality-of-life-improvement-and-caregiver-behavior-data-at-two-recent-hae-congresses/